Open AccessEfficacy of Pomegranate Seed Powder on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes: A Prospective Randomized Double-Blind Placebo-Controlled Clinical Trial
Author(s) -
Monire Seyed Hashemi,
Nasim Namiranian,
Hemaseh Tavahen,
Abolfazl Dehghanpour,
M H Rad,
Saeedeh Jam-Ashkezari,
Majid Emtiazy,
Mohammad Hashem Hashempur
Publication year - 2020
Publication title -
complementary medicine research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.238
H-Index - 38
eISSN - 2504-2106
pISSN - 2504-2092
DOI - 10.1159/000510986
Subject(s) - medicine , glycated hemoglobin , placebo , triglyceride , diabetes mellitus , gastroenterology , cholesterol , type 2 diabetes mellitus , randomized controlled trial , lipid profile , type 2 diabetes , glycated haemoglobin , clinical trial , carbohydrate metabolism , endocrinology , traditional medicine , alternative medicine , pathology
Pomegranate is known as a functional food which has multiple health-promoting activities. It has been assessed for patients with metabolic syndrome. Specifically, an antidiabetic activity of its juice and plausible mechanisms for its action have been shown in multitudinous studies. The aim of this study was assessing the effects of complementary treatment with pomegranate seed powder (PSP) oral supplementation on patients with type 2 diabetes mellitus (T2DM). Methods: Sixty patients were treated for 8 weeks by 5 g PSP or placebo, twice daily. Fasting blood glucose (FBG), glycated hemoglobin (HbA 1c ), total cholesterol, and triglyceride (TG) were recorded as the outcome measures at the beginning and after the intervention. The findings were analyzed using the independent t test and Mann-Whitney U test. Results: After 8 weeks, the mean differences of FBG, HbA 1c , cholesterol, and TG were significantly decreased in the PSP group when compared with the placebo group ( p value <0.05). In addition, post-intervention values of FBG and HbA 1c were significantly lower in patients treated with PSP compared to the placebo group ( p values = 0.02 and 0.01, respectively). However, the latter comparison regarding cholesterol and TG showed no significant differences ( p values = 0.51 and 0.26, respectively). Conclusion: It seems that complementary treatment with PSP may have beneficial effects on FBG and HbA 1c of patients with T2DM. However, its effect on TG and cholesterol was equivocal.